100 results
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
services agreement pursuant to which we and BioNTech may access and leverage each other’s manufacturing and commercial capabilities with respect … to certain CAR-T products, including BioNTech’s product candidate BNT211. This agreement, if entered into, would also grant BioNTech access to our
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
may obtain access to BioNTech’s manufacturing and commercial site services capabilities for Autolus’s CAR-T products, and (ii) BioNTech may obtain … access to Autolus’s manufacturing and commercial site services capabilities for BioNTech’s CAR-T products, including the product known as BNT211 (“BNT211
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
clinical trial activities, such as clinical trial site monitoring, access to capital, and potential disruption in the operations and business of third … the external supply arrangements also provide for access to services including quality management systems, qualified persons for product release, office
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
. The focus of this collaboration has been sort of on three key platforms that we have developed. The first one is providing access to BioNTech to our … that platform. And then also, obviously, the access to two of our product candidates, AUTO1/22 and AUTO6NG in a co-development, co-commercialization options
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
on net sales BioNTech has co-commercialization options for Autolus’ AUTO1/22 and AUTO6NG programs, and an option to access a suite of Autolus target … , which are required to access the conference call. A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website
8-K
EX-99.1
e9mr8lhndnethx
13 Feb 24
Regulation FD Disclosure
4:06pm
424B5
rc9zfodf3zalwtawlzk3
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-1.1
977v1nlw
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
wkqjszvgu18sj
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-10.1
17w5wqpka 73x
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-99.1
v90rxviq40l668l
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-10.3
jftacfdlm7q en
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-10.2
h6t5ksemk13yibk39gxn
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
8j4ouow9cl4gw
7 Feb 24
Automatic shelf registration
10:00pm
8-K
EX-99.1
j1efpii
11 Dec 23
Regulation FD Disclosure
8:31am
10-Q
EX-10.2
4c5b 87l8cr6obq3
9 Nov 23
Quarterly report
4:18pm
10-Q
EX-10.1
kf3940c5u 4oo95qxetw
9 Nov 23
Quarterly report
4:18pm
10-Q
d10y7yonndqx9f
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.3
6s1 jc7jcz
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.2
rwh57
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm